Armata Pharmaceuticals Reports Positive Phase 2 Study Results

Armata Pharmaceuticals ( (ARMP) ) has issued an announcement.

Armata Pharmaceuticals announced positive results from its Phase 2 Tailwind study evaluating AP-PA02, an inhaled phage therapy for non-cystic fibrosis bronchiectasis patients with chronic Pseudomonas aeruginosa infections. The study demonstrated a statistically significant reduction in bacterial colony forming units, suggesting the potential of phage therapy to reduce reliance on chronic antibiotic use. AP-PA02 was well-tolerated with mild adverse events, highlighting its promising safety profile. These findings support Armata’s mission to develop phage-based therapeutics as new treatment alternatives for chronic pulmonary diseases.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant and difficult-to-treat bacterial infections. The company is advancing a broad pipeline of both natural and synthetic phage candidates, including those targeting Pseudomonas aeruginosa and Staphylococcus aureus. Armata leverages its proprietary bacteriophage-based technology and in-house phage-specific cGMP manufacturing capabilities to support full commercialization.

YTD Price Performance: -39.81%

Average Trading Volume: 8,317

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $70.56M

See more data about ARMP stock on TipRanks’ Stock Analysis page.